This suggests that passive immunization with tau antibodies can be a practical therapeutic target and that the CSF level of p-tau262/356 or on the microtubule binding domain (MTBD) can serve as a beneficial biomarker of tau pathology to watch tau therapeutics in clinical trials.Their Tale laid the inspiration for what exactly is shaping up to be a